Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Infectious Disease

Your Treatment Roadmap: Understanding PB and MB Classifications

At a Glance

Hansen's disease (leprosy) is classified into two types to determine your exact treatment length. Paucibacillary (PB) involves 1 to 5 skin lesions and requires 6 months of medication. Multibacillary (MB) involves 6 or more lesions or a positive skin smear, requiring 12 months of treatment.

When you are diagnosed with Hansen’s disease, your care team will use specific terms to categorize your infection. These classifications—Paucibacillary (PB) and Multibacillary (MB)—are not a measure of your worth or a “grade” of how sick you are [1]. Instead, they are practical tools that tell your doctor exactly which medications you need and how long you need to take them [2][3].

The Two Main Categories: PB vs. MB

The World Health Organization (WHO) uses a straightforward system to group patients based on the visible signs of the disease and the number of bacteria present [1][4]:

  • Paucibacillary (PB): “Pauci” means few. This type is diagnosed if you have 1 to 5 skin lesions [1]. In PB cases, a test called a slit-skin smear (a small scrape from the skin) will typically show no visible bacteria [5]. Because there are fewer bacteria to clear, the standard treatment duration is 6 months [1][2].
  • Multibacillary (MB): “Multi” means many. This type is diagnosed if you have 6 or more skin lesions [1]. It is also classified as MB if the slit-skin smear test is positive for bacteria, regardless of how many lesions you have [6][7]. Because the bacterial load is higher, the treatment is more intensive and lasts for 12 months [1][3].

The Biology: The Ridley-Jopling Spectrum

While the PB/MB system is used for treatment planning, doctors also look at a more detailed biological scale called the Ridley-Jopling classification [8][9]. This scale explains why your body is reacting the way it is. It maps your body’s immune response on a spectrum:

  • Tuberculoid (TT/BT): At this end of the spectrum, your immune system is working very hard to “wall off” the bacteria [8][9]. (Note: This is just a historical medical term; it does NOT mean you have tuberculosis [8].) This usually results in just a few, well-defined skin patches with very few bacteria (matching the PB category) [10].
  • Lepromatous (LL/BL): At this end, the immune system is less effective at targeting the bacteria, allowing them to multiply more freely [8][9]. This leads to more widespread skin spots and a higher bacterial count (matching the MB category) [6].
  • Borderline: Many people fall somewhere in the middle, where their immune response is in a state of flux [11][12].

Why Classification Matters for You

The classification system is essentially a “roadmap” for your cure. It ensures that patients with more bacteria get enough medicine to prevent the disease from coming back (relapse), while ensuring patients with fewer bacteria aren’t taking medication longer than necessary [13][14].

Regardless of your classification, the goal is exactly the same: to kill the bacteria, protect your nerves, and return you to full health [15][16]. Your doctor may perform a skin biopsy or a nerve ultrasound to help place you accurately on this spectrum and ensure your roadmap is perfectly tailored to your needs [17][18]. Although there is some clinical debate about whether a single 6-month regimen could work for everyone, current global standards still use these specific categories to guide your path to recovery [19][3].

Common questions in this guide

What is the difference between PB and MB classifications?
Paucibacillary (PB) means you have 1 to 5 skin lesions and fewer bacteria, which requires 6 months of treatment. Multibacillary (MB) means you have 6 or more lesions or a positive skin test, which requires a more intensive 12-month treatment plan.
What does a positive slit-skin smear mean for my treatment?
A positive slit-skin smear indicates a higher number of bacteria are present in your skin. Regardless of how few skin lesions you may have, a positive test automatically classifies your condition as Multibacillary (MB), meaning you will need the 12-month treatment regimen.
What is the Ridley-Jopling spectrum?
The Ridley-Jopling spectrum is a detailed medical scale that maps how your unique immune system is reacting to the bacteria. It ranges from Tuberculoid, where your immune system aggressively walls off the bacteria, to Lepromatous, where the bacteria are able to multiply more freely.
Does a Tuberculoid classification mean I have tuberculosis?
No, it does not mean you have tuberculosis. Tuberculoid is simply a historical medical term used to describe a strong immune response in Hansen's disease, resulting in just a few, well-defined skin patches.
Why do treatment lengths vary between 6 and 12 months?
Treatment length is tailored to the amount of bacteria in your body to prevent the disease from returning. Patients with fewer bacteria only need 6 months of medicine, while those with higher bacterial loads need 12 months to ensure the infection is completely cured.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my lesion count and skin smear results, have I been classified as Paucibacillary (PB) or Multibacillary (MB)?
  2. 2.What was my 'bacteriological index' from the slit-skin smear, and how does it influence my diagnosis?
  3. 3.Where do I fall on the Ridley-Jopling spectrum (e.g., Tuberculoid or Lepromatous), and what does that tell us about my immune response?
  4. 4.How will we monitor my progress to ensure the standard treatment duration (6 or 12 months) is sufficient for my case?
  5. 5.If I have fewer than 5 lesions but a positive skin smear, will my treatment plan be adjusted to the MB regimen?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Leprosy.

    Grijsen ML, Nguyen TH, Pinheiro RO, et al.

    Nature reviews. Disease primers 2024; (10(1)):90 doi:10.1038/s41572-024-00575-1.

    PMID: 39609422
  2. 2

    Clinical and Histopathological Response to Multidrug Therapy in Paucibacillary Leprosy at the end of 6 Months: A Prospective Observational Study from Eastern India.

    Podder I, Saha A, Bandyopadhyay D

    Indian journal of dermatology 2018; (63(1)):47-52 doi:10.4103/ijd.IJD_80_17.

    PMID: 29527025
  3. 3

    Late relapses in leprosy patients in Brazil: 10-year post-trial of uniform multidrug therapy (U-MDT/CT-BR).

    Penna GO, Pontes MAA, Talhari S, et al.

    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2024; (28(2)):103745 doi:10.1016/j.bjid.2024.103745.

    PMID: 38697216
  4. 4

    Clinicobacteriological evaluation of leprosy patients with 1-5 skin lesions.

    Ansari AS, Saxena K, Singh KK, et al.

    International journal of mycobacteriology 2020; (9(2)):209-211 doi:10.4103/ijmy.ijmy_7_20.

    PMID: 32474546
  5. 5

    Renaissance of Hansen's Disease in Post-Elimination Era in North India: A Retrospective Clinico-Bacteriological Study.

    Hazarika N, Gupta PK, Dhanta A, et al.

    Cureus 2021; (13(8)):e17514 doi:10.7759/cureus.17514.

    PMID: 34603886
  6. 6

    A Study of Clinical, Bacteriological & Histopathological Correlation in Leprosy Cases attending a Government Medical College in Western Odisha: Some Observations.

    Kakkad K, Padhi T, Pradhan K, Agrawal KC

    Indian journal of leprosy 2016; (88(2)):97-103.

    PMID: 29757541
  7. 7

    Multibacillary Leprosy Presenting as Anetoderma in a Young Teenager.

    Parajuli N, Shrestha S, Lama L, et al.

    Case reports in dermatological medicine 2020; (2020()):8847310 doi:10.1155/2020/8847310.

    PMID: 32802526
  8. 8

    Reciprocity between Regulatory T Cells and Th17 Cells: Relevance to Polarized Immunity in Leprosy.

    Sadhu S, Khaitan BK, Joshi B, et al.

    PLoS neglected tropical diseases 2016; (10(1)):e0004338 doi:10.1371/journal.pntd.0004338.

    PMID: 26751584
  9. 9

    Cytokine polarized natural killer T cells modulate effector T cell function in leprosy.

    Sadhu S, Mitra DK, Jain S, Dige MA

    Cytokine 2026; (201()):157130 doi:10.1016/j.cyto.2026.157130.

    PMID: 41722150
  10. 10

    Temporal-spatial distribution characteristics of leprosy: A new challenge for leprosy prevention and control in Zhejiang, China.

    Wu L, Shen Y, Yao Q, et al.

    PLoS neglected tropical diseases 2021; (15(1)):e0008956 doi:10.1371/journal.pntd.0008956.

    PMID: 33411800
  11. 11

    Concordance of Acid-Fast Stain Result and Histopathologic vs Clinical Diagnosis of Leprosy: A Three-year Retrospective Study in a Tertiary Government Hospital and Sanitarium in the Philippines.

    Gochoco JBB, Bernales-Mendoza AM

    Acta medica Philippina 2024; (58(23)):42-48 doi:10.47895/amp.vi0.8317.

    PMID: 39830415
  12. 12

    Correlation of Clinico-pathological Classification of Hansen's Disease in a South Indian City.

    Lobo AC, Pai RR, Gautam K, Kuruvila M

    Indian journal of leprosy 2014; (86(4)):147-54.

    PMID: 26411247
  13. 13

    Implications of Serum Anti-Ceramide Antibodies and Interleukin 4 on Nerve Damage and Physical Impairments Among Leprotic Patients: A Case-Controlled Study.

    Zaky M, Obaid Z, Khedr M, et al.

    Journal of drugs in dermatology : JDD 2022; (21(3)):284-291 doi:10.36849/JDD.5543.

    PMID: 35254767
  14. 14

    Treatment neglect in multibacillary leprosy leading to osteomyelitis and transtibial amputation: Lessons from endemic setting.

    Gunawan H, Ruchiatan K, Avriyanti E, et al.

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2026; (164()):108354 doi:10.1016/j.ijid.2025.108354.

    PMID: 41455488
  15. 15

    Functional Impairment of Skin Appendages Due to Peripheral Nerve Involvement by Mycobacterium leprae.

    Granger DL, Rosado-Santos H, Lo TS, et al.

    Open forum infectious diseases 2020; (7(10)):ofaa419 doi:10.1093/ofid/ofaa419.

    PMID: 33094119
  16. 16

    Beyond Classic Leprosy: Exploring Atypical Manifestations and Their Diagnostic Challenges.

    Bathina A, Kollipara H, Sravani G, Laxmi VS

    Cureus 2024; (16(12)):e75957 doi:10.7759/cureus.75957.

    PMID: 39834975
  17. 17

    A Clinicohistopathological Correlation of Hansen's Disease in a Rural Tertiary Care Hospital of Central India.

    Atram MA, Ghongade PV, Gangane NM

    Journal of global infectious diseases 2020; (12(4)):191-196 doi:10.4103/jgid.jgid_58_20.

    PMID: 33888956
  18. 18

    Hansen's disease in the era of COVID-19: An observation on a series of six patients with co-infection.

    Arora S, Bhatnagar A, Singh GK, et al.

    Dermatologic therapy 2021; (34(2)):e14827 doi:10.1111/dth.14827.

    PMID: 33527634
  19. 19

    Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients.

    Penna GO, Bührer-Sékula S, Kerr LRS, et al.

    PLoS neglected tropical diseases 2017; (11(7)):e0005725 doi:10.1371/journal.pntd.0005725.

    PMID: 28704363

This page explains Hansen's disease classifications for educational purposes only. Your infectious disease specialist or dermatologist is the best source for interpreting your specific test results and determining your treatment plan.

Get notified when new evidence is published on Leprosy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.